CN114832057B - 一种抑菌妇科凝胶及其制备方法 - Google Patents
一种抑菌妇科凝胶及其制备方法 Download PDFInfo
- Publication number
- CN114832057B CN114832057B CN202210344297.8A CN202210344297A CN114832057B CN 114832057 B CN114832057 B CN 114832057B CN 202210344297 A CN202210344297 A CN 202210344297A CN 114832057 B CN114832057 B CN 114832057B
- Authority
- CN
- China
- Prior art keywords
- parts
- astaxanthin
- microcapsule
- water
- gynecological gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 52
- 238000001879 gelation Methods 0.000 title description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 145
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 145
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 145
- 239000001168 astaxanthin Substances 0.000 claims abstract description 145
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 145
- 239000003094 microcapsule Substances 0.000 claims abstract description 105
- 239000002994 raw material Substances 0.000 claims abstract description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920001661 Chitosan Polymers 0.000 claims abstract description 54
- 239000011248 coating agent Substances 0.000 claims abstract description 26
- 238000000576 coating method Methods 0.000 claims abstract description 26
- 239000000419 plant extract Substances 0.000 claims abstract description 25
- 239000008213 purified water Substances 0.000 claims abstract description 21
- 239000011162 core material Substances 0.000 claims abstract description 12
- 239000003906 humectant Substances 0.000 claims abstract description 11
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 10
- 241001116389 Aloe Species 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 7
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 7
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 7
- 241001145025 Saussurea involucrata Species 0.000 claims abstract description 7
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 35
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 14
- 230000000975 bioactive effect Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 230000003385 bacteriostatic effect Effects 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 241000220317 Rosa Species 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- 229910052709 silver Inorganic materials 0.000 claims description 9
- -1 silver ions Chemical class 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 241000050051 Chelone glabra Species 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 241000972673 Phellodendron amurense Species 0.000 claims description 3
- 240000006688 Telosma cordata Species 0.000 claims description 3
- 235000017352 Telosma cordata Nutrition 0.000 claims description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 3
- 241000213006 Angelica dahurica Species 0.000 claims 1
- 241000382455 Angelica sinensis Species 0.000 abstract description 6
- 244000144927 Aloe barbadensis Species 0.000 abstract 1
- 235000002961 Aloe barbadensis Nutrition 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 241000207925 Leonurus Species 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241001573366 Astragalus membranaceus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 244000137773 Viola philippica Species 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical group N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本申请涉及卫生用品领域,具体公开了一种抑菌妇科凝胶及其制备方法。一种抑菌妇科凝胶,由包括以下重量份的原料制备得到:植物提取液17‑220份,芦荟3‑5份,虾青素微胶囊6‑10份,凝胶基质20‑40份;保湿剂0.5‑1份;纯化水A补充妇科凝胶总重量为1000份;植物提取液由包括以下原料制备得到:苦参,蛇床子,黄柏,天山雪莲,黄芩,益母草,当归,白芍,黄芪,紫花地丁,女贞子,乌梅;芦荟;虾青素微胶囊的包括内包衣、外包衣和芯材,内包衣包括水溶性壳聚糖,外包衣为壳聚糖,芯材为虾青素。本申请的一种抑菌妇科凝胶具有提高妇科凝胶中虾青素稳定性,进而提高妇科凝胶抑菌效果的优点。
Description
技术领域
本申请涉及卫生用品领域,更具体地说,它涉及一种抑菌妇科凝胶及其制备方法。
背景技术
当今社会女性群体越来越关注自身亚健康问题,其中妇科炎症中的阴道炎、宫颈糜烂等是困扰女性的常见病。妇科凝胶是一种妇科药品,为凝胶剂,用于各种妇科阴道炎、宫颈炎的治疗,包括:细菌性阴道炎、滴虫性阴道炎、混合性阴道炎、淋球菌感染、慢性宫颈炎。具有消炎、杀菌、止痒作用。对金黄色葡萄球菌、大肠杆菌、淋球菌、白色念珠球菌、真菌、酵母菌等病原体微生物的生长有明显抑制作用。相关技术中为了提高妇科凝胶的抗菌消炎作用,制备妇科凝胶的原料中还添加有虾青素。
针对上述中的相关技术,发明人发现虾青素易受光、热、氧等氧化降解而失去活性,从而影响妇科凝胶的抑菌效果。
发明内容
为了提高妇科凝胶中虾青素的稳定性,进而提高妇科凝胶的抑菌效果,本申请提供一种抑菌妇科凝胶及其制备方法。
第一方面,本申请提供一种抑菌妇科凝胶,采用如下的技术方案:
一种抑菌妇科凝胶,由包括以下重量份的原料制备得到:
植物提取液17-220份,芦荟3-5份,虾青素微胶囊6-10份,凝胶基质20-40份;保湿剂0.5-1份;纯化水A补充至1000份;
以植物提取液的重量为基准,所述植物提取液由包括以下重量份的原料制备得到:苦参200-300份,蛇床子150-200份,黄柏80-120份,天山雪莲60-90份,黄芩40-70份,益母草90-120份,当归80-110份,白芍20-40份,黄芪50-80份,紫花地丁50-80份,女贞子60-90份,乌梅30-50份;芦荟20-40份;
所述虾青素微胶囊的包括内包衣、外包衣和芯材,所述内包衣包括水溶性壳聚糖,所述外包衣为壳聚糖,所述芯材为虾青素。
通过采用上述技术方案,由于采用苦参、蛇床子、黄柏、天山雪莲、黄芩、益母草、当归、白芍、黄芪、紫花地丁、女贞子、乌梅、芦荟这些天然物质的添加,使得妇科凝胶具备抑菌、清热解毒的效果;虾青素具备抗氧化性和增强机体免疫力的特性,作为原料添加至妇科凝胶中能够进一步提高妇科凝胶的抑菌效果。
水溶性壳聚糖和壳聚糖在pH<5.6的酸性条件下逐渐降解,如此,当水溶性壳聚糖作为内包衣,即可将虾青素包裹成水包油的小液滴,再以壳聚糖作为外包衣,即可使得虾青素微胶囊在凝胶体系中形成小液滴,如此制备得到的虾青素微胶囊随妇科凝胶进入pH在3.8-4.2阴道内时,虾青素即可自虾青素微胶囊中缓慢释放,并直接作用于阴道,降低了虾青素失活而导致抑菌作用失效的可能,采用水溶性壳聚糖和壳聚糖包裹虾青素提高了妇科凝胶中虾青素的稳定性,从而显著提高了妇科凝胶的抑菌效果。
保湿剂的加入能够妇科凝胶的保存时间,降低妇科凝胶在储存和使用过程中变质的可能。
如此,本申请中妇科凝胶采用由虾青素作为芯材、水溶性壳聚糖作为内包衣、壳聚糖作为外包衣的虾青素微胶囊作为原料,使得虾青素在存放和运输过程中能够被包裹,使用时进入pH为3.8-4.2的阴道后能够缓慢释放并作用于阴道,从而能够有效降低虾青素提前失活而导致其抑菌作用失效的可能,提高了妇科凝胶中虾青素的稳定性,进而显著提高了妇科凝胶的抑菌效果。
可选的,以虾青素微胶囊的重量为基准,所述虾青素微胶囊由包括如下重量份的原料制备得到:虾青素17-19份,水溶性壳聚糖30-40份,水60-80份,壳聚糖40-50份,乙醇70-80份。
通过采用上述技术方案,水溶性壳聚糖能够溶解在水中,虾青素不具备水溶性,向溶解有水溶性壳聚糖的水中加入虾青素,虾青素即可分散在水中形成水包油小液滴;壳聚糖能够溶解在乙醇中,水溶性壳聚糖包裹的虾青素小液滴即可分散在溶解有壳聚糖的乙醇中,形成外包衣为壳聚糖、内包衣为水溶性壳聚糖、芯材为虾青素的虾青素微胶囊。
可选的,所述虾青素微胶囊由包括以下步骤的方法制备得到:
制备基础微胶囊:边搅拌边向水中加入水溶性壳聚糖,持续搅拌3-5min得到水相,边搅拌边向水相加入虾青素,静置3-5min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向乙醇中加入壳聚糖持续搅拌3-5mi得到油相,边搅拌边向油相加入基础微胶囊,静置3-5min得到虾青素微胶囊。
通过采用上述技术方案,能够使得虾青素、壳聚糖以及水溶性壳聚糖形成内包衣为水溶性壳聚糖、外包衣为壳聚糖、芯材为虾青素的虾青素微胶囊。
可选的,以虾青素微胶囊的重量为基准,所述虾青素微胶囊的内包衣还包括15-20份维生素C乙基醚。
通过采用上述技术方案,维生素C乙基醚是一种维生素C衍生物,不仅能够稳定存在,还更易被皮肤吸收,使皮肤变得充盈富有弹性、细腻光滑;还能够抑制酪氨酸酶活性,抑制黑色素的形成,还原黑色素为无色,高效美白肌肤;强效抗菌消炎作用。并且维生素C乙基醚和虾青素复配,提高了抗坏血酸和虾青素的稳定性,两者协同增效,极大的提高了妇科凝胶的抑菌效果。
可选的,所述虾青素微胶囊由包括以下步骤的方法制备得到:
制备基础微胶囊:边搅拌边向水中加入水溶性壳聚糖和维生素C乙基醚,持续搅拌3-5min得到水相,边搅拌边向水相加入虾青素,静置3-5min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向乙醇中加入壳聚糖持续搅拌3-5mi得到油相,边搅拌边向油相加入基础微胶囊,静置3-5min得到虾青素微胶囊。
通过采用上述技术方案,能够制备得内包衣为水溶性壳聚糖和维生素C乙基醚、外内衣为壳聚糖、芯材为虾青素的虾青素微胶囊。
可选的,所述抑菌妇科凝胶的原料还包括1-2份银离子。
通过采用上述技术方案,银离子具有优良的杀菌作用,银离子的加入能够进一步提高妇用凝胶的抑菌效果。
可选的,所述抑菌妇科凝胶的原料还包括3-5份玫瑰精油。
通过采用上述技术方案,玫瑰精油是纯天然植物精油,玫瑰精油具有抗菌、抗痉挛、杀菌、催情、净化、镇静、补身等功效,能够消炎杀菌、防传染病、防发炎,防痉挛、促进细胞新陈代谢及细胞再生功能;还能调节内分泌器官,并适用于各种皮肤,发挥紧实、舒缓的特性,滋养皮肤,延缓衰老;玫瑰精油的添加能够与原料中的其他成分共同作用,进一步提高妇科凝胶的抑菌作用。
可选的,所述抑菌妇科凝胶的原料还包括2-3份生物活性肽,且所述生物活性肽为抗菌肽。
通过采用上述技术方案,生物活性肽是源于蛋白质的多功能化合物;具有多种人体代谢和生理调节功能,易消化吸收,有促进免疫、激素调节、抗菌、抗病毒、降血压、降血脂等作用;抗菌肽的加入能够与原料中的其他成分共同作用,从而提高妇科凝胶的抑菌作用。
第二方面,本申请提供一种抑菌妇科凝胶的制备方法,采用如下的技术方案:一种抑菌妇科凝胶的制备方法,包括以下步骤:
制备植物提取液:将苦参、蛇床子、黄柏、天山雪莲、黄芩、益母草、当归、白芍、黄芪、紫花地丁、女贞子、乌梅磨成粉末得到粉体原料,将粉体原料浸泡在粉体原料总重量8-10倍的纯化水B,浸泡8h-15h后进行煎煮,煎煮1-2.5h后得到煎煮药液A,再向粉体原料中加入粉体原料总重量8-10倍的纯化水B,继续煎煮1-2h后得到煎煮药液B,压榨两次煎煮后的粉体原料得到压榨液,混合压榨液、煎煮药液A和煎煮药液B得到混合液,将混合液在40-60℃下浓缩2-4h后得到植物提取液;
制备水溶液:边搅拌边向纯化水A中加入植物提取液和除虾青素微胶囊外的其他原料得到凝胶基液;
制备妇科凝胶:边搅拌边向凝胶基液中加入虾青素微胶囊得到妇科凝胶。
通过采用上述技术方案,最后添加虾青素微胶囊能够降低虾青素微胶囊在前期搅拌过程中提前破裂而失活的可能,能够更好地保持虾青素微胶囊稳定性,从而提高妇科凝胶的抑菌效果。
综上所述,本申请具有以下有益效果:
1、由于本申请采用内包衣为水溶性壳聚糖、外包衣为壳聚糖、芯材为虾青素的虾青素微胶囊,当虾青素微胶囊随妇科凝胶进入pH在3.8-4.2阴道内时,虾青素即可自虾青素微胶囊中缓慢释放,并直接作用于阴道,降低了虾青素失活而导致抑菌作用失效的可能,从而显著提高了妇科凝胶的抑菌效果。
2、本申请中采用维生素C乙基醚与虾青素复配,提高了维生素C乙基醚与虾青素的稳定性,从而提高了妇科凝胶的抑菌效果。
3、本申请原料中添加银离子、玫瑰精油、生物活性肽,使其与原料中的其他成分共同作用,进一步提高妇科凝胶的抑菌作用。
具体实施方式
以下结合实施例对本申请作进一步详细说明,予以特别说明的是:以下实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行,以下实施例中所用原料除特殊说明外均可来源于普通市售。
生物活性肽为乳链菌肽;
凝胶基质为卡波姆;
保湿剂为甘油。
虾青素微胶囊的制备例
制备例1
一种虾青素微胶囊的制备方法,包括以下步骤:
制备基础微胶囊:边搅拌边向60kg水中加入30kg水溶性壳聚糖,持续搅拌3min得到水相,边搅拌边向水相加入17kg虾青素,静置3min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向70kg乙醇中加入40kg壳聚糖持续搅拌3min得到油相,边搅拌边向油相加入基础微胶囊,静置3min得到虾青素微胶囊。
制备例2
一种虾青素微胶囊的制备方法,包括以下步骤:边搅拌边向80kg水中加入40kg水溶性壳聚糖,持续搅拌5min得到水相,边搅拌边向水相加入19kg虾青素,静置5min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向80kg乙醇中加入50kg壳聚糖持续搅拌5min得到油相,边搅拌边向油相加入基础微胶囊,静置5min得到虾青素微胶囊。
制备例3
一种虾青素微胶囊的制备方法,包括以下步骤:边搅拌边向70kg水中加入35kg水溶性壳聚糖,持续搅拌4min得到水相,边搅拌边向水相加入18kg虾青素,静置4min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向75kg乙醇中加入45kg壳聚糖持续搅拌4min得到油相,边搅拌边向油相加入基础微胶囊,静置4min得到虾青素微胶囊。
制备例4
一种虾青素微胶囊的制备方法,按照制备例3中方法进行,不同之处在于,原料还包括15kg维生素C乙基醚,维生素C乙基醚和水溶性壳聚糖一同加入水中得到水相。
制备例5
一种虾青素微胶囊的制备方法,按照制备例3中方法进行,不同之处在于,原料还包括20kg维生素C乙基醚,维生素C乙基醚和水溶性壳聚糖一同加入水中得到水相。
制备例6
一种虾青素微胶囊的制备方法,按照制备例3中方法进行,不同之处在于,原料还包括18kg维生素C乙基醚,维生素C乙基醚和水溶性壳聚糖一同加入水中得到水相。
虾青素微胶囊的对比制备例
对比制备例1
一种虾青素微胶囊的制备方法,按照制备例6中方法进行,不同之处在于,原料18kg维生素C乙基醚等重量替换为18kg虾青素。
对比制备例2
一种虾青素微胶囊的制备方法,按照制备例6中方法进行,不同之处在于,原料还包括18kg虾青素等重量替换为18kg维生素C乙基醚。
实施例
实施例1
一种抑菌妇科凝胶的制备方法,包括以下步骤:
制备植物提取液:将200kg苦参、150kg蛇床子、80kg黄柏、60kg天山雪莲、40kg黄芩、90kg益母草、80kg当归、20kg白芍、50kg黄芪、50kg紫花地丁、60kg女贞子、30kg乌梅、20kg芦荟磨成粉末得到粉体原料,将粉体原料浸泡在粉体原料总重量8倍的纯化水B,浸泡8h后进行煎煮,煎煮1h后得到煎煮药液A,再向粉体原料中加入粉体原料总重量8倍的纯化水B,继续煎煮1h后得到煎煮药液B,压榨两次煎煮后的粉体原料得到压榨液,混合压榨液、煎煮药液A和煎煮药液B得到混合液,将混合液在40℃下浓缩2h后得到植物提取液;
制备水溶液:边搅拌边向803.5kg纯化水A中加入170kg植物提取液,20kg凝胶基质,0.5kg保湿剂得到凝胶基液;
制备妇科凝胶:边搅拌边向凝胶基液中加入6kg由制备例1中方法制备得到的虾青素微胶囊得到妇科凝胶。
实施例2
一种抑菌妇科凝胶的制备方法,包括以下步骤:
制备植物提取液:将300kg苦参、200kg蛇床子、120kg黄柏、90kg天山雪莲、70kg黄芩、120kg益母草、110kg当归、40kg白芍、80kg黄芪、80kg紫花地丁、90kg女贞子、50kg乌梅、40kg芦荟磨成粉末得到粉体原料,将粉体原料浸泡在粉体原料总重量10倍的纯化水B,浸泡15h后进行煎煮,煎煮2.5h后得到煎煮药液A,再向粉体原料中加入粉体原料总重量10倍的纯化水B,继续煎煮2h后得到煎煮药液B,压榨两次煎煮后的粉体原料得到压榨液,混合压榨液、煎煮药液A和煎煮药液B得到混合液,将混合液在60℃下浓缩4h后得到植物提取液;
制备水溶液:边搅拌边向729kg纯化水A中加入220kg植物提取液,40kg凝胶基质,1kg保湿剂得到凝胶基液;
制备妇科凝胶:边搅拌边向凝胶基液中加入10kg由制备例1中方法制备得到的虾青素微胶囊得到妇科凝胶。
实施例3
一种抑菌妇科凝胶的制备方法,包括以下步骤:
制备植物提取液:将250kg苦参、180kg蛇床子、100kg黄柏、75kg天山雪莲、55kg黄芩、105kg益母草、95kg当归、30kg白芍、65kg黄芪、65kg紫花地丁、60kg女贞子、40kg乌梅、30kg芦荟磨成粉末得到粉体原料,将粉体原料浸泡在粉体原料总重量9倍的纯化水B,浸泡11h后进行煎煮,煎煮2h后得到煎煮药液A,再向粉体原料中加入粉体原料总重量9倍的纯化水B,继续煎煮2h后得到煎煮药液B,压榨两次煎煮后的粉体原料得到压榨液,混合压榨液、煎煮药液A和煎煮药液B得到混合液,将混合液在50℃下浓缩3h后得到植物提取液;
制备水溶液:边搅拌边向761kg纯化水A中加入200kg植物提取液,30kg凝胶基质,1kg保湿剂得到凝胶基液;
制备妇科凝胶:边搅拌边向凝胶基液中加入8kg由制备例1中方法制备得到的虾青素微胶囊得到妇科凝胶。
实施例4
一种抑菌妇科凝胶的制备方法,按照实施例3中方法进行,不同之处在于,原料中8kg虾青素微胶囊由制备例2中方法制备得到。
实施例5
一种抑菌妇科凝胶的制备方法,按照实施例3中方法进行,不同之处在于,原料中8kg虾青素微胶囊由制备例3中方法制备得到。
实施例6、
一种抑菌妇科凝胶的制备方法,按照实施例3中方法进行,不同之处在于,原料中8kg虾青素微胶囊由制备例4中方法制备得到。
实施例7
一种抑菌妇科凝胶的制备方法,按照实施例3中方法进行,不同之处在于,原料中8kg虾青素微胶囊由制备例5中方法制备得到。
实施例8
一种抑菌妇科凝胶的制备方法,按照实施例3中方法进行,不同之处在于,原料中8kg虾青素微胶囊由制备例6中方法制备得到。
实施例9
一种抑菌妇科凝胶的制备方法,按照实施例8中方法进行,不同之处在于,原料中还包括1.5kg银离子;边搅拌边向759.5kg纯化水A中加入200kg植物提取液,30kg凝胶基质,1kg保湿剂和1.5kg银离子得到凝胶基液。
实施例10
一种抑菌妇科凝胶的制备方法,按照实施例8中方法进行,不同之处在于,原料中还包括4kg玫瑰精油;边搅拌边向757kg纯化水A中加入200kg植物提取液,30kg凝胶基质,1kg保湿剂和4kg玫瑰精油得到凝胶基液。
实施例11
一种抑菌妇科凝胶的制备方法,按照实施例8中方法进行,不同之处在于,原料中还包括2.5kg生物活性肽;边搅拌边向758.5kg纯化水A中加入200kg植物提取液,30kg凝胶基质,1kg保湿剂和2.5kg生物活性肽得到凝胶基液。
对比例
对比例1
一种抑菌妇科凝胶的制备方法,按照实施例5中方法进行,不同之处在于,原料中不添加虾青素微胶囊。
对比例2
一种抑菌妇科凝胶的制备方法,按照实施例5中方法进行,不同之处在于,原料中8kg虾青素微胶囊等重量替换为8kg虾青素。
对比例3
一种抑菌妇科凝胶的制备方法,按照实施例5中方法进行,不同之处在于,原料中8kg虾青素微胶囊等重量替换为3kg虾青素和5kg水溶性壳聚糖。
对比例4
一种抑菌妇科凝胶的制备方法,按照实施例8中方法进行,不同之处在于,原料中8kg虾青素微胶囊由对比制备例1中方法制备得到。
对比例5
一种抑菌妇科凝胶的制备方法,按照实施例8中方法进行,不同之处在于,原料中8kg虾青素微胶囊由对比制备例2中方法制备得到。
性能检测试验
按照GB15979-2002《一次性使用卫生用品卫生标准》附录C的方法,对上述实施例和对比例进行大肠杆菌、白色念珠菌以及金黄色葡萄球菌的抑菌效果测试,测试结果如表1所示。
表1:
结合实施例5和对比例1-3,以及他们在表1中数据可以看出,相较于实施例5,对比例1的不同之处在于,原料中不添加虾青素微胶囊;对比例2的不同之处在于,原料中8kg虾青素微胶囊等重量替换为8kg虾青素;对比例3的不同之处在于,原料中8kg虾青素微胶囊等重量替换为3kg虾青素和5kg水溶性壳聚糖。对比例1-3中得到的妇科凝胶大肠杆菌、白色念珠菌以及金黄色葡萄球菌的抑菌率均显著低于实施例5,说明实施例5中采用由虾青素和水溶性壳聚糖制备得到的虾青素微胶囊作为原料,能够显著提升妇科凝胶的抑菌效果。
其根本原因在于,本申请中采用由虾青素作为芯材、水溶性壳聚糖作为包衣的虾青素微胶囊作为原料,使得虾青素在存放和运输过程中能够被包裹,使用时进入pH为3.8-4.2的阴道后能够缓慢释放并作用于阴道,从而能够有效降低虾青素提前失活而导致其抑菌作用失效的可能,提高了妇科凝胶中虾青素的稳定性,进而显著提高了妇科凝胶的抑菌效果。
结合实施例8和对比例4-5、实施例5以及表1的数据可以发现,不同于实施例8,对比例4的不同之处在于,在制备虾青素微胶囊时,虾青素微胶囊原料中18kg维生素C乙基醚等重量替换为18kg虾青素;对比例5的不同之处在于,在制备虾青素微胶囊时,虾青素微胶囊原料中18kg虾青素等重量替换为18kg维生素C乙基醚;实施例5的不同之处在于,在制备虾青素微胶囊时,虾青素微胶囊原料中不含有维生素C乙基醚。而实施例8中得到的妇科凝胶大肠杆菌、白色念珠菌以及金黄色葡萄球菌的抑菌率不仅远远高于对比例4和对比例5,还明显优于实施例5。
说明实施例8中在制备虾青素微胶囊时,采用虾青素与维生素C乙基醚作为虾青素微胶囊的原料能够显著提高虾青素微胶囊的抑菌作用,从而显著提高妇科凝胶的抑菌效果。其原因在于,虾青素与维生素C乙基醚复配,提高了抗坏血酸和虾青素的稳定性,从而降低了抗坏血酸和虾青素失活而导致抑菌作用失效的可能,两者协同增效,极大的提高了妇科凝胶的抑菌效果。
结合实施例8和实施例9-11并结合表1可以看出,相较于实施例8,实施例9的不同之处在于,原料还包括有银离子;实施例10的不同之处在于,原料还包括有玫瑰精油;实施例11的不同之处在于,原料还包括有生物活性肽。实施例9-11中得到的妇科凝胶大肠杆菌、白色念珠菌以及金黄色葡萄球菌的抑菌率,相较于实施例8均有所提高;说明在妇科凝胶制备过程中,在原料中添加银离子、玫瑰精油、生物活性肽均能提高妇科凝胶的抑菌效果。
本具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (8)
1.一种抑菌妇科凝胶,其特征在于,由包括以下重量份的原料制备得到:
植物提取液17-220份,虾青素微胶囊6-10份,凝胶基质20-40份;保湿剂0.5-1份;纯化水A补充至1000份;
以植物提取液的重量为基准,所述植物提取液由以下重量份的原料制备得到:苦参200-300份,蛇床子150-200份,黄柏80-120份,天山雪莲60-90份,黄芩40-70份,益母草90-120份,当归80-110份,白芍20-40份,黄芪50-80份,紫花地丁50-80份,女贞子60-90份,乌梅30-50份;芦荟20-40份;
所述虾青素微胶囊由内包衣、外包衣和芯材组成,所述内包衣包括水溶性壳聚糖,所述外包衣为壳聚糖,所述芯材为虾青素;
以虾青素微胶囊的重量为基准,所述虾青素微胶囊由包括如下重量份的原料制备得到:虾青素17-19份,水溶性壳聚糖30-40份,水60-80份,壳聚糖40-50份,乙醇70-80份。
2.根据权利要求1所述的一种抑菌妇科凝胶,其特征在于:所述虾青素微胶囊由包括以下步骤的方法制备得到:
制备基础微胶囊:边搅拌边向水中加入水溶性壳聚糖,持续搅拌3-5min得到水相,边搅拌边向水相加入虾青素,静置3-5min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向乙醇中加入壳聚糖持续搅拌3-5min得到油相,边搅拌边向油相加入基础微胶囊,静置3-5min得到虾青素微胶囊。
3.根据权利要求1所述的一种抑菌妇科凝胶,其特征在于:以虾青素微胶囊的重量为基准,所述虾青素微胶囊的内包衣还包括15-20份维生素C乙基醚。
4.根据权利要求3所述的一种抑菌妇科凝胶,其特征在于:所述虾青素微胶囊由包括以下步骤的方法制备得到:
制备基础微胶囊:边搅拌边向水中加入水溶性壳聚糖和维生素C乙基醚,持续搅拌3-5min得到水相,边搅拌边向水相加入虾青素,静置3-5min得到基础微胶囊;
制备虾青素微胶囊:边搅拌边向乙醇中加入壳聚糖持续搅拌3-5min得到油相,边搅拌边向油相加入基础微胶囊,静置3-5min得到虾青素微胶囊。
5.根据权利要求1所述的一种抑菌妇科凝胶,其特征在于:所述抑菌妇科凝胶的原料还包括1-2份银离子。
6.根据权利要求1所述的一种抑菌妇科凝胶,其特征在于:所述抑菌妇科凝胶的原料还包括3-5份玫瑰精油。
7.根据权利要求1所述的一种抑菌妇科凝胶,其特征在于:所述抑菌妇科凝胶的原料还包括2-3份生物活性肽,且所述生物活性肽为抗菌肽。
8.如权利要求1-7中任一项所述的一种抑菌妇科凝胶的制备方法,其特征在于,包括以下步骤:
制备植物提取液:将苦参、蛇床子、黄柏、天山雪莲、黄芩、益母草、当归、白芍、黄芪、紫花地丁、女贞子、乌梅、芦荟磨成粉末得到粉体原料,将粉体原料浸泡在粉体原料总重量8-10倍的纯化水B,浸泡8h-15h后进行煎煮,煎煮1-2.5h后得到煎煮药液A,再向粉体原料中加入粉体原料总重量8-10倍的纯化水B,继续煎煮1-2h后得到煎煮药液B,压榨两次煎煮后的粉体原料得到压榨液,混合压榨液、煎煮药液A和煎煮药液B得到混合液,将混合液在40-60℃下浓缩2-4h后得到植物提取液;
制备水溶液:边搅拌边向纯化水A中加入植物提取液和除虾青素微胶囊外的其他原料得到凝胶基液;
制备妇科凝胶:边搅拌边向凝胶基液中加入虾青素微胶囊得到妇科凝胶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210344297.8A CN114832057B (zh) | 2022-04-02 | 2022-04-02 | 一种抑菌妇科凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210344297.8A CN114832057B (zh) | 2022-04-02 | 2022-04-02 | 一种抑菌妇科凝胶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114832057A CN114832057A (zh) | 2022-08-02 |
CN114832057B true CN114832057B (zh) | 2024-01-16 |
Family
ID=82563321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210344297.8A Active CN114832057B (zh) | 2022-04-02 | 2022-04-02 | 一种抑菌妇科凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114832057B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112206308A (zh) * | 2020-11-21 | 2021-01-12 | 陕西远志医药生物工程有限公司 | 一种滋养抑菌凝胶及其制备方法 |
CN112316017A (zh) * | 2020-11-19 | 2021-02-05 | 陕西康乐实业有限公司 | 一种妇科抑菌凝胶及其制备方法 |
CN112999289A (zh) * | 2019-12-19 | 2021-06-22 | 陕西康乐实业有限公司 | 一种妇科抑菌凝胶及其制备方法 |
CN113134066A (zh) * | 2021-05-07 | 2021-07-20 | 诸暨市博美生物科技有限公司 | 一种妇科凝胶的制作方法 |
-
2022
- 2022-04-02 CN CN202210344297.8A patent/CN114832057B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112999289A (zh) * | 2019-12-19 | 2021-06-22 | 陕西康乐实业有限公司 | 一种妇科抑菌凝胶及其制备方法 |
CN112316017A (zh) * | 2020-11-19 | 2021-02-05 | 陕西康乐实业有限公司 | 一种妇科抑菌凝胶及其制备方法 |
CN112206308A (zh) * | 2020-11-21 | 2021-01-12 | 陕西远志医药生物工程有限公司 | 一种滋养抑菌凝胶及其制备方法 |
CN113134066A (zh) * | 2021-05-07 | 2021-07-20 | 诸暨市博美生物科技有限公司 | 一种妇科凝胶的制作方法 |
Non-Patent Citations (1)
Title |
---|
张辰等.虾青素对牛子宫内膜细胞炎症损伤的保护作用.《中国农业科学》.2019,第52卷(第52期),3049-3058. * |
Also Published As
Publication number | Publication date |
---|---|
CN114832057A (zh) | 2022-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108524866A (zh) | 一种中药抑菌凝胶剂及其制备方法 | |
CN112870137A (zh) | 一种女性私密护理液用复合原料及其制备方法 | |
CN113057930A (zh) | 一种含迷迭香的除螨面霜及其制备方法 | |
CN111228207B (zh) | 祛湿疹护臀霜及其制备方法 | |
CN1053116C (zh) | 中药美容面膜 | |
CN103100075B (zh) | 一种治疗湿疹的药剂 | |
CN114832057B (zh) | 一种抑菌妇科凝胶及其制备方法 | |
CN110538299B (zh) | 乌发防脱控油祛屑除螨外用药液及其制备方法 | |
CN108078903B (zh) | 一种植物祛痘组合物及其制备方法 | |
CN1164407A (zh) | 一种治疗烧伤、创疡的新药及制备方法 | |
WO1998050055A1 (en) | Ointment for the treatment of burns and of other skin diseases | |
CN112870311A (zh) | 一种女性私密处抑菌水凝胶及使用方法 | |
CN111658586A (zh) | 一种具有除螨祛痘的中药组合物及其制备方法和应用 | |
CN113134066A (zh) | 一种妇科凝胶的制作方法 | |
CN112190605A (zh) | 抑菌消炎组合物及其制备方法 | |
CN110840800A (zh) | 一种产后专用沐浴露及其制备方法 | |
CN111494259A (zh) | 一种本草抑菌消毒液 | |
CN103041071A (zh) | 一种治疗斑秃、脱发、皮肤落屑瘙痒的中药擦剂 | |
CN110585239B (zh) | 一种膏药及其制备方法和应用 | |
CN110946903B (zh) | 用于防治系统性硬化病的中药组合物及其应用 | |
CN112587713B (zh) | 一种具有抗菌功能的新型卫生巾及其生产工艺 | |
CN112263667A (zh) | 作用于女性生殖道健康的中药生物制剂及其制备方法 | |
CN114832065B (zh) | 一种治疗痤疮的中药组合物、制剂及其制备方法 | |
CN101716231A (zh) | 外用涂抹治疗斑秃的生发液 | |
CN112641857A (zh) | 对阴部有嫩红和抑菌作用的中药生物制剂及配制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |